NCT05759728View on ClinicalTrials.gov

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Colorectal Cancer Metastatic
Interventions
BIOLOGICAL

CNA3103: 5 x 10^7 cells

CNA3103: 5 x 10\^7 cells - intravenous infusion

BIOLOGICAL

CNA3103: 1.5 x 10^8 cells

CNA3103: 1.5 x 10\^8 cells - intravenous infusion

BIOLOGICAL

CNA3103: 4.5 x 10^8 cells

CNA3103: 4.5 x 10\^8 cells - intravenous infusion

BIOLOGICAL

CNA3103: 1.5 x 10^9 cells

CNA3103: 1.5 x 10\^9 cells - intravenous infusion

BIOLOGICAL

CNA3103: 2.5 x 10^7 cells

CNA3103: 2.5 x 10\^7 cells - intravenous infusion

Trial Locations (1)

5000

RECRUITING

Carina Biotech Investigators, Adelaide

Sponsors
All Listed Sponsors
lead

Carina Biotech Limited

INDUSTRY